Published in Menopause on July 01, 2012
Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA (2006) 4.39
Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry (2002) 3.13
Methodologic lessons learned from hot flash studies. J Clin Oncol (2001) 2.82
Laboratory and ambulatory monitoring of menopausal hot flashes. Psychophysiology (1989) 2.34
Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol (2008) 1.93
Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med (2005) 1.86
Emotional antecedents of hot flashes during daily life. Psychosom Med (2005) 1.77
The middle-range theory of unpleasant symptoms: an update. ANS Adv Nurs Sci (1997) 1.66
Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. Menopause (2012) 1.65
Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life. Cancer (1998) 1.65
Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat (2007) 1.61
Mindfulness training for coping with hot flashes: results of a randomized trial. Menopause (2011) 1.61
Cognitive behavioral therapy techniques for distress and pain in breast cancer patients: a meta-analysis. J Behav Med (2006) 1.55
Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric (2007) 1.50
Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol (2009) 1.46
Quality of life after the menopause: a population study. Maturitas (2000) 1.41
Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric (2006) 1.40
Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy. Menopause (2009) 1.24
Hot flashes: behavioral treatments, mechanisms, and relation to sleep. Am J Med (2005) 1.16
Behavioral treatment of menopausal hot flushes: evaluation by ambulatory monitoring. Am J Obstet Gynecol (1992) 1.15
Menopausal symptoms in women with breast cancer: prevalence and treatment preferences. Psychooncology (2004) 1.11
A psychological analysis of menopausal hot flushes. Br J Clin Psychol (1995) 1.07
Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J Pain Symptom Manage (2000) 1.05
Laboratory and ambulatory evaluation of vasomotor symptom monitors from the Menopause Strategies Finding Lasting Answers for Symptoms and Health network. Menopause (2012) 1.03
Support Vector Machines to improve physiologic hot flash measures: application to the ambulatory setting. Psychophysiology (2010) 1.02
Clinical update: psychosocial responses in breast cancer survivors. Semin Oncol Nurs (2011) 0.99
Relationships between catastrophic thoughts, perceived control and distress during menopausal hot flushes: exploring the correlates of a questionnaire measure. Maturitas (2000) 0.97
A randomised controlled trial of a cognitive behavioural intervention for women who have menopausal symptoms following breast cancer treatment (MENOS 1): trial protocol. BMC Cancer (2011) 0.93
Feasibility study of acupuncture for reducing sleep disturbances and hot flashes in postmenopausal breast cancer survivors. Clin Nurse Spec (2012) 0.84
Effect of yoga on menopausal symptoms. Menopause Int (2011) 0.83
Clinical trials in integrative therapies. Semin Oncol Nurs (2012) 0.81
A randomised controlled trial of cognitive-behavioural therapy for women with problematic menopausal hot flushes: MENOS 2 trial protocol. BMJ Open (2011) 0.78
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol (2004) 7.36
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med (2003) 6.99
Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol (2010) 4.30
Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2005) 4.10
Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med (2008) 2.74
Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol (2010) 2.57
Pathophysiology and treatment of hot flashes. Mayo Clin Proc (2002) 2.56
An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol (2004) 2.45
The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer (2010) 2.43
Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol (2013) 2.43
Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol (2002) 2.33
Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3. J Natl Cancer Inst (2007) 2.31
Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol (2010) 2.28
Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol (2002) 2.09
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer (2007) 1.94
Efficacy of complementary and alternative medicine therapies in relieving cancer pain: a systematic review. J Clin Oncol (2006) 1.82
Acupuncture for hot flashes: a randomized, sham-controlled clinical study. Menopause (2007) 1.78
Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol (2008) 1.77
Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol (2006) 1.76
Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol (2006) 1.68
Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol (2004) 1.66
Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol (2010) 1.61
The prevalence of weight concerns in a smoking abstinence clinical trial. Addict Behav (2005) 1.60
A pilot study of long-acting octreotide for symptomatic malignant ascites. Oncology (2012) 1.56
Pilot evaluation of black cohosh for the treatment of hot flashes in women. Cancer Invest (2004) 1.55
Symptom control trials: a 20-year experience. J Support Oncol (2007) 1.48
Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc (2002) 1.48
Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst (2013) 1.47
Gadgets for measuring hot flashes: have they become the gold standard? J Support Oncol (2009) 1.44
Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation. Support Care Cancer (2002) 1.44
A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer (2010) 1.41
Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer (2008) 1.40
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer (2005) 1.40
Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol (2004) 1.40
Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. J Clin Oncol (2003) 1.36
High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology (2008) 1.34
Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res (2013) 1.33
Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer (2009) 1.28
Epoetin alfa and darbepoetin alfa go head to head. J Clin Oncol (2006) 1.27
Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken) (2013) 1.25
Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol (2012) 1.24
Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain (2002) 1.24
Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol (2010) 1.21
Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc (2006) 1.20
Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain (2010) 1.19
Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc (2007) 1.19
Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine. J Palliat Med (2005) 1.17
Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol (2006) 1.14
The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer (2011) 1.12
Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer (2005) 1.11
Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions. Int J Womens Health (2010) 1.11
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat (2009) 1.09
Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer. Cancer (2008) 1.08
Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol (2010) 1.07
Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4. Int J Radiat Oncol Biol Phys (2010) 1.07
Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer (2014) 1.07
Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist (2003) 1.07
Symptom management in premenopausal patients with breast cancer. Lancet Oncol (2008) 1.07
Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy. Ann Neurol (2014) 1.06
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast (2010) 1.03
Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Support Care Cancer (2010) 1.03
Erythropoietin use in cancer patients: a matter of life and death? J Clin Oncol (2005) 1.03
A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer (2007) 1.03
Chemotherapy-induced ovarian failure: manifestations and management. Drug Saf (2005) 1.02
Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol (2004) 1.02
Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4). Int J Radiat Oncol Biol Phys (2010) 1.02
Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. Support Care Cancer (2014) 1.02
Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys (2007) 1.01
A critical review of complementary therapies for cancer-related fatigue. Integr Cancer Ther (2007) 0.99
Treatment of hot flushes in breast and prostate cancer. Expert Opin Pharmacother (2005) 0.98
Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol (2006) 0.97
Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience. Menopause (2008) 0.96
Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol (2010) 0.95
Newer antidepressants for hot flashes--should their efficacy still be up for debate? Menopause (2009) 0.95
A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7. Menopause (2012) 0.94
Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. Oncologist (2011) 0.94
A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer (2009) 0.91
Pilot evaluation of flaxseed for the management of hot flashes. J Soc Integr Oncol (2007) 0.91
Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clin Proc (2004) 0.90
Physical activity and the risk of breast cancer recurrence: a literature review. Oncol Nurs Forum (2012) 0.90
Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. Neurotoxicology (2013) 0.89
Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist (2010) 0.88
Pilot evaluation of a stellate ganglion block for the treatment of hot flashes. Support Care Cancer (2010) 0.88
Therapeutic strategies for cancer treatment related peripheral neuropathies. Curr Treat Options Oncol (2014) 0.88
Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB. J Support Oncol (2010) 0.87